Apellis Pharmaceuticals, Inc. (APLS)
17.21
-0.76
(-4.23%)
USD |
NASDAQ |
Mar 20, 16:00
17.21
0.00 (0.00%)
After-Hours: 20:00
Apellis Pharmaceuticals Research and Development Expense (Quarterly) : 74.23M for Dec. 31, 2025
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Amneal Pharmaceuticals, Inc. | 36.23M |
| Alnylam Pharmaceuticals, Inc. | 372.22M |
| BioMarin Pharmaceutical, Inc. | 192.41M |
| Amicus Therapeutics, Inc. | 23.74M |
| Ionis Pharmaceuticals, Inc. | 279.36M |